Fate Therapeutics, Inc. (FATE) is a publicly traded Healthcare sector company. As of May 20, 2026, FATE trades at $1.93 with a market cap of $201.65M and a P/E ratio of -1.69. FATE moved +1.85% today. Year to date, FATE is +91.61%; over the trailing twelve months it is +54.92%. Its 52-week range spans $0.66 to $3.80. Analyst consensus is buy with an average price target of $4.46. Rallies surfaces FATE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who is trading FATE stock inside the company?
Recent FATE insider activity includes TAHL CINDY sold 10.59K, Valamehr Bahram sold 5.19K, TAHL CINDY sold 9.04K, Valamehr Bahram sold 14.47K, and Bressi Jerome Charles sold 5.98K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
FATE Key Metrics
Key financial metrics for FATE
Metric
Value
Price
$1.93
Market Cap
$201.65M
P/E Ratio
-1.69
EPS
$-1.09
Dividend Yield
0.00%
52-Week High
$3.80
52-Week Low
$0.66
Volume
1.46M
Avg Volume
0
Revenue (TTM)
$6.32M
Net Income
$-129.91M
Gross Margin
0.00%
Recent FATE Insider Trades
TAHL CINDY sold 10.59K (~$11.28K) on Jan 9, 2026.
Valamehr Bahram sold 5.19K (~$5.56K) on Jan 9, 2026.
TAHL CINDY sold 9.04K (~$9.57K) on Aug 4, 2025.
Valamehr Bahram sold 14.47K (~$15.40K) on Aug 4, 2025.
Bressi Jerome Charles sold 5.98K (~$9.27K) on Jan 10, 2025.
Recent FATE insider activity includes TAHL CINDY sold 10.59K, Valamehr Bahram sold 5.19K, TAHL CINDY sold 9.04K, Valamehr Bahram sold 14.47K, and Bressi Jerome Charles sold 5.98K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for FATE?
Yes. Rallies tracks FATE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is FATE research on Rallies investment advice?
No. Rallies provides research, data, and educational context for FATE. It does not provide personalized investment advice.
